Asenapine in the treatment of borderline personality disorder: An atypical antipsychotic alternative

Ana Martín-Blanco, Barbara Patrizi, Laia Villalta, Xero Gasol, Joaquim Soler, Miquel Gasol, Juan C. Pascual

Research output: Contribution to journalArticleResearchpeer-review

13 Citations (Scopus)

Abstract

Many individuals with borderline personality disorder (BPD) receive medical treatment in clinical practice, although to date, there are no drugs specifically available for BPD. The recent Cochrane guideline suggests a benefit from using second-generation antipsychotics such as olanzapine or aripiprazole; nevertheless, side effects limit their use. Asenapine is a novel FDA-approved atypical antipsychotic for schizophrenia and bipolar disorder. However, it has not yet been tested for BPD. The goal of this observational open-label study was to assess the safety, tolerability and efficacy of asenapine in a series of cases of patients with BPD. Twelve individuals with BPD were recruited and treated with asenapine during an 8-week period. Eight individuals completed the study; a significant improvement was observed in the CGI-BPD (P<0.001) and BSL-23 (P<0.048) scales for BPD symptomatology. Besides, there was a significant improvement in the general psychopathology domains (BPRS, P<0.004), whereas no significant differences were observed in depressive symptoms. No serious adverse effects were reported and a significant weight reduction was observed (P=0.002). Asenapine appears to be a safe and effective agent in the treatment of patients with BPD, especially when other alternatives are not tolerated. These preliminary findings should be replicated in a controlled clinical trial. Copyright © Lippincott Williams & Wilkins.
Original languageEnglish
Pages (from-to)120-123
JournalInternational Clinical Psychopharmacology
Volume29
Issue number2
DOIs
Publication statusPublished - 1 Mar 2014

Keywords

  • Antipsychotics
  • Asenapine
  • Borderline Personality Disorder
  • Treatment

Fingerprint

Dive into the research topics of 'Asenapine in the treatment of borderline personality disorder: An atypical antipsychotic alternative'. Together they form a unique fingerprint.

Cite this